Physician profile
Jebin M Chacko
NPI 1598778458
$1,059.18
in general payments reported to CMS, 2019-2025
12 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $104 · 2021: $122 · 2022: $81.99 · 2023: $256 · 2024: $114 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $314.65 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $178.76 | 2019-2025 | Zilbrysq |
| Alexion Pharmaceuticals, INC. | $156.00 | 2019-2023 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $139.56 | 2019-2022 | |
| Allergan, INC. | $78.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $37.81 | 2021 | |
| Lilly USA, LLC | $33.54 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $32.94 | 2019 | |
| Acorda Therapeutics, INC | $22.90 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.04 | 2021 | |
| Abbvie INC. | $21.93 | 2021 | |
| Sk Life Science, INC. | $20.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jebin Chacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.